Faruqi and Faruqui, LLP Logo
Share this page

Dr. Reddy's Laboratories Limited (RDY)

NYSE:RDY

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Dr. Reddy's Laboratories Limited To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE:RDY).

On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration (“FDA”) regarding inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. On this news, shares of Dr. Reddy’s fell $11.75 per share or 18.01% to close at $53.50 on November 6, 2015.

Then, on August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary, Betapharm Arzneimittel.  On this news, Dr. Reddy's share price declined.

If you invested in Dr. Reddy's stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Dr. Reddy's Laboratories Limited (RDY)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 08/10/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.